DE60042496D1 - USE OF RETINOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF BONE AND CARTIL PATHOLOGIES - Google Patents

USE OF RETINOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF BONE AND CARTIL PATHOLOGIES

Info

Publication number
DE60042496D1
DE60042496D1 DE60042496T DE60042496T DE60042496D1 DE 60042496 D1 DE60042496 D1 DE 60042496D1 DE 60042496 T DE60042496 T DE 60042496T DE 60042496 T DE60042496 T DE 60042496T DE 60042496 D1 DE60042496 D1 DE 60042496D1
Authority
DE
Germany
Prior art keywords
treatment
bone
cartil
pathologies
retinoid receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042496T
Other languages
German (de)
Inventor
Maurizio Pacifici
Roshantha A Chandraratna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
University of Pennsylvania Penn
Original Assignee
Allergan Inc
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, University of Pennsylvania Penn filed Critical Allergan Inc
Application granted granted Critical
Publication of DE60042496D1 publication Critical patent/DE60042496D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Abstract

Use of a retinoid receptor antagonist for the manufacture of a medicament for the treatment of a cartilage or bone pathology, wherein the antagonist is: where n is an integer from 1 to 10; or a pharmaceutically acceptable salt thereof.
DE60042496T 1999-12-15 2000-12-13 USE OF RETINOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF BONE AND CARTIL PATHOLOGIES Expired - Lifetime DE60042496D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/464,344 US6313168B1 (en) 1999-12-15 1999-12-15 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
PCT/US2000/033697 WO2001043732A2 (en) 1999-12-15 2000-12-13 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies

Publications (1)

Publication Number Publication Date
DE60042496D1 true DE60042496D1 (en) 2009-08-13

Family

ID=23843560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042496T Expired - Lifetime DE60042496D1 (en) 1999-12-15 2000-12-13 USE OF RETINOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF BONE AND CARTIL PATHOLOGIES

Country Status (8)

Country Link
US (1) US6313168B1 (en)
EP (2) EP1645271A1 (en)
JP (1) JP4808887B2 (en)
AT (1) ATE435010T1 (en)
AU (1) AU784189B2 (en)
CA (1) CA2394210A1 (en)
DE (1) DE60042496D1 (en)
WO (1) WO2001043732A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111695A1 (en) * 1995-11-06 2002-08-15 Mount Sinai Hospital Corporation Reconstituted mineralized cartilage tissue
CA2402413A1 (en) * 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
AU2002325752A1 (en) * 2001-09-17 2003-04-01 The University Of Western Ontario Retinoid receptor pan-antagonists for stimulating chondrogenesis
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
AU2003302070A1 (en) * 2002-11-15 2004-06-15 Galderma Research And Development, S.N.C. USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFBeta
FR2847167A1 (en) * 2002-11-15 2004-05-21 Galderma Res & Dev Method for treating disorders associated with TGF-beta signal deficiency, e.g. cicatrization disorders, ulcers, cancers or graft rejection, comprises administration of retinoic acid receptor-Gamma antagonists
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
EP1701934B1 (en) * 2003-12-26 2009-02-25 Allergan, Inc. DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
SI1937244T1 (en) 2005-09-30 2018-12-31 Io Therapeutics, Llc Treatment of cancer with specific rxr agonists
DK2026778T3 (en) * 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
EP2613776B1 (en) 2010-09-01 2020-07-29 Thomas Jefferson University Composition and method for muscle repair and regeneration
MX352727B (en) 2011-12-13 2017-12-06 Dartmouth College Autoimmune disorder treatment using rxr agonists.
EP2918290B1 (en) 2012-11-08 2020-09-02 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
EP3446690A1 (en) 2013-05-22 2019-02-27 Yamaguchi University Inhibitor for retinochoroidal disorders
PL3368080T3 (en) 2015-10-31 2023-09-11 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
KR20230164204A (en) 2016-03-10 2023-12-01 아이오 테라퓨틱스, 인크. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
EP3426303B1 (en) 2016-03-10 2022-06-15 IO Therapeutics, Inc. Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
EP4249490A3 (en) 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
KR20190100187A (en) 2016-11-16 2019-08-28 클레멘티아 파마슈티컬즈, 인크. How to Treat Multiple Osteochondroma (MO)
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011755A1 (en) 1991-12-18 1993-06-24 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5514825A (en) 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5648514A (en) 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
DE19501032A1 (en) * 1995-01-14 1996-07-18 Max Delbrueck Centrum Agent for treating rheumatic diseases esp. arthritis
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5808124A (en) 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
DE19910246A1 (en) * 1999-03-08 2000-09-28 Bayer Ag Easy-to-separate molded polyurethane foam systems
DK1161410T3 (en) * 1999-03-08 2004-09-20 Basilea Pharmaceutica Ag Retinoid antagonists and their use

Also Published As

Publication number Publication date
AU784189B2 (en) 2006-02-16
CA2394210A1 (en) 2001-06-21
EP1645271A1 (en) 2006-04-12
WO2001043732A2 (en) 2001-06-21
JP4808887B2 (en) 2011-11-02
US6313168B1 (en) 2001-11-06
ATE435010T1 (en) 2009-07-15
EP1248602A2 (en) 2002-10-16
JP2003519103A (en) 2003-06-17
AU2259301A (en) 2001-06-25
EP1248602B1 (en) 2009-07-01
WO2001043732A3 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
ATE435010T1 (en) USE OF RETINOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF BONE AND CARTILAGE PATHOLOGIES
ATE182591T1 (en) 5-HT4 RECEPTOR ANTAGONISTS
ATE266655T1 (en) DIBENZOPYRANE AS GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SUBJECT DISEASE
ATE175114T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AN OPIATE ANTAGONIST AND CALCIUM SALTS, THEIR USE FOR THE TREATMENT OF ENDORPHIN-MEDIATED DISEASES
JO2371B1 (en) 4-phenyl -pyridine derivatives
DE60218493D1 (en) SUBSTITUTED 7-AZA-Ä2.2.1ÜBICYCLOHEPTANE FOR THE TREATMENT OF DISEASES
EA200100524A1 (en) AMIDES OF ANTRANILIC ACID AND THEIR APPLICATION AS MEDICINES
DE69724777D1 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
ATE284693T1 (en) USE OF DOPAMINE-D 3 RECEPTOR ANTAGONISTS FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF RENAL DISORDERS
DE50011178D1 (en) SUBSTITUTED 1,5-DIHYDROPYRROL-2-ON DERIVATES HAVE EFFECTIVE AS NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN STATES
DE60204951D1 (en) CCR5 ANTAGONISTS USE FOR THE TREATMENT OF AIDS
ES2087038B1 (en) NEW PIPERIDINES WITH ANTAGONIST ACTIVITY OF THE PAF.
DE60014339D1 (en) ARYL- AND HETEROARYL-CONDENSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF THE GABAA RECEPTORS
NO20014241D0 (en) C16-unsaturated FP-selective prostaglandin analogs
DE60042446D1 (en) USE OF ANTAGONISTS OF 5-HT3 RECEPTORS FOR THE TREATMENT OF MUSCULOSCELETAL DISEASES
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
EE200100553A (en) Use of saredutant and pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment or prevention of mood disorders, adaptive disorders, or mixed anxiety depressive disorders.
DE60108094D1 (en) THE USE OF RETINOID ANTAGONISTS OR AGONISTS FOR THE TREATMENT OF JOINT AND BONE PATHOLOGIES
DE69622889D1 (en) SUBSTITUTED 4- (1H-BENZIMIDAZOL-2-YL) (1,4) DIAZEPANE FOR THE TREATMENT OF ALLERGIC DISEASES
PT896822E (en) 4-AMINOPYROLOL (3,2-D) PYRIMIDINES AS ANTAGONISTS OF THE NEUROPEPTIDEO RECEPTOR AND
PT804186E (en) ALCALOID DITERPENIC COMPOUNDS FROM INDOLE
DE69918541D1 (en) USE OF NMDA ANTAGONISTS FOR THE TREATMENT COLON
BR0206687A (en) Method to prevent and treat visceral pain and gastrointestinal disorders
HUP9904030A2 (en) Use of tiagabine for production of pharmaceutical against psychotic disorders
DE60132436D1 (en) RETINOLIC ACID RECEPTOR BETA-2 AND GENETHERAPY VECTORS FOR THE TREATMENT OF NEUROLOGICAL DISEASES

Legal Events

Date Code Title Description
8364 No opposition during term of opposition